Sep 22, 2018

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis

Respirology Case Reports
Kentaro FukunagaYasutaka Nakano


A 76-year-old man with a past history of acute exacerbation (AE) and idiopathic pulmonary fibrosis (IPF) was treated with nintedanib because of decline in his forced vital capacity over time. A new small nodular lesion was visible on a computed tomography scan of the chest before initiation of nintedanib. Disease progression in IPF and change in size of the nodular lesion were not detected during administration of nintedanib. Nine months after starting nintedanib, the patient was diagnosed with acute gangrenous appendicitis, and nintedanib treatment was discontinued. The nodular lesion increased in size four months after the cessation of nintedanib. The nodular lesion was diagnosed as squamous cell carcinoma. In this case, nintedanib inhibited the disease progression of IPF and lung cancer simultaneously. Nintedanib may play an important role in the treatment of IPF-associated lung cancer.

  • References5
  • Citations3


Mentioned in this Paper

Lung Growth
Transcription Initiation
X-Ray Computed Tomography
Vital Capacity Test
Administration Procedure
Carcinoma of Lung
Adverse Event
Anterior Thoracic Region

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.